Feed EVO
EV

Evotec SE

EVO · NASDAQ

$1.58 +1.94% (+$0.03)
1M -18.52%
Market Cap 477.1M €
P/E Ratio -
Div. Yield -
ROE 26.85%
Piotroski F-Score Moderate
4/9
Valuation
100 /100
Cheap
P/B 0.72x
P/S 0.66x
EV/FFO N/A
Growth
16 /100
Declining
Book val. growth 11.84%
Rev. growth 0.26%
FCF growth N/A
Profitability
1 /100
Weak
Op. margin 17.89%
Gross margin 10.34%
FCF margin 23.39%
Quality
6 /100
Poor
ROA 12.70%
ROIC 10.41%
Asset turnover 0.46x
Debt
54 /100
Moderate
Int. coverage -15.75x
Debt/Equity 0.71x
Current ratio 2.33x
Stability
45 /100
Moderate
EPS volatility 112.60%
Beta 1.26x
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about EVO
Online

About the company

Evotec SE (EVT) is a German pharmaceutical company focused on drug research and development. The company provides services to pharmaceutical and biotechnology firms in the areas of drug discovery, testing, and drug development. Evotec collaborates with various research institutions and pharmaceutical companies worldwide to identify and develop new drugs for different diseases. The company specializes in areas such as oncology, neurology, metabolic disorders, and infectious diseases. Evotec has a long history of research and innovation in the pharmaceutical industry, and its technologies and expertise are highly regarded in the world of medical research. Evotec SE (EVT) shares may be an attractive investment opportunity for investors interested in the pharmaceutical sector and seeking an investment in a company with a significant role in discovering new drugs and therapeutic approaches.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Christian Wojczewski

Employees

4,553

Headquarters

Hamburg

Upcoming events

05 NOV

Earnings

Upcoming earnings report

44d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.